Focus

• Focus on serving patients and protecting public health.
• US$13.7 million supporting product access across the world.*
• CSL Vifor integration is well advanced with synergies on track.
• Multiple manufacturing yield initiatives underway.
• Achieved 98 product registrations or new indications in 34 countries around the globe.
• HEMGENIX^® (Haemophilia B gene therapy) launched in the United States.
• FERINJECT^® approved in China for the treatment of iron deficiency in adult patients.
• INJECTAFER^® approved in the United States for the treatment of iron deficiency in adult patients with heart failure.
• TAVNEOS^® (avacopan) approved in Australia for the treatment of ANCA- associated vasculitis.

Innovation

• Research and development (R&D) investment of US$1.2 billion.*
• US$42.6 million in global community investment across our strategic areas of support.
• HIZENTRA^® (Immune Globulin Subcutaneous (Human) 20% Liquid) Pre-Filled Syringe approved by the FDA.
• BERINERT^® S.C. Injection 2000 (lyophilised human C1-esterase inhibitor concentrate) approved by Japan MHLW.
• Garadacimab (Anti-FXIIa mAb) Phase III study met its primary and secondary endpoints, demonstrating that monthly subcutaneous injections of garadacimab significantly reduced attack rate compared to placebo in patients with Hereditary Angioedema.
• CSL112 (ApoA-1) enrolment in Phase III study complete.
• Clazakizumab (Anti-IL-6 mAb) Phase IIb/III study commenced in patients with end stage kidney disease.
• KAPRUVIA^® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus.
• Phase II study for aQIVc (adjuvanted QIV cell-based influenza vaccine) completed.
• A licence agreement was signed with Arcturus Therapeutics for late-stage next-generation mRNA vaccine technology.

Efficiency and reliable supply

• Record levels of plasma collections.
• In 2022/23, 12 new plasma collection centres opened.
• 130 million influenza vaccine doses distributed by CSL Seqirus.
• Base fractionation capacity completed at Broadmeadows and Marburg.
• Participated in 475 regulatory inspections of our manufacturing facilities and plasma collection centres.*

Sustainable growth

• A strong year with underlying profit (NPATA) of US$2.61 billion for the 12 months ended 30 June 2023, up 20% on a constant currency¹ basis when compared to the prior comparable period.
• Strong growth in Immunoglobulins portfolio, up 21% at constant currency¹.
• CSL Seqirus revenue up 9% at constant currency¹ driven by strong growth in FLUCELVAX.
• US$13.2 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.*
• Across CSL’s European manufacturing facilities, achieved 100% renewable electricity purchased from certified sources.

Digital transformation

• CSL Plasma App which has been downloaded over 3 million times, with more than 530,000 users logged in every month.
• Continuing to support life and data scientists with automation, artificial intelligence and stronger data and analytics platforms.
• CSL R&D is using digital technology and analytics to simulate, automate, monitor and enhance productivity and experimentation. These technologies offer new insights through the use of big data sets generated by CSL platforms, and have the potential to fundamentally change the way CSL works in R&D.

People and culture

• 76.2% employee engagement* index.
• 44% women at the Board level and 59% women across the Group*.
• Early career programs for STEM talent around the globe help to build CSL’s future talent pipeline.
• Wide range of professional and personal development programs to meet the evolving needs of current and future leaders.
• Ranked among the best large employers in America by Forbes magazine and named to Forbes Global 2000; also among Work180 Top Workplaces for Women in Australia and Prosple Top 100 Graduate Employers in Australia.

* Limited assurance by Ernst & Young.

¹ Constant currency (CC) removes the impact of exchange rate movements, facilitating the comparability of operational performance. For further detail refer to CSL’s Financial Statements for the Full Year ended June 2023 (Directors Report).